More Ad-interim Injunctions Obtained | Boehringer Ingelheim IN

Boehringer Ingelheim’s injunctions over the past nine months against domestic pharmaceutical manufacturers are -
- Two absolute injunctions upholding the patent rights of Empagliflozin
- One absolute injunction and four ad-interim injunctions against generic versions of Boehringer Ingelheim’s patented Linagliptin drug
The recent four injunctions restrain domestic drugmakers from infringing the Patent of Linagliptin marketed under the trade name, ‘Trajenta’, in the country.
This emphasizes the strengths of Boehringer Ingelheim’s patents.

India, 07 June 2022 – Boehringer Ingelheim, one of the world’s leading, research-driven pharmaceutical companies, has obtained ad-interim injunctions against four domestic pharmaceutical companies that launched generic versions of Boehringer Ingelheim’s patent-protected drug Linagliptin, which is marketed under the brand name, Trajenta.

The recent injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making, using, offering for sale, selling, importing and/or exporting in any form in India either by themselves or through their directors, partners licenses, stockiest and distributors, agents etc., jointly and severally until the next date of hearing.

Boehringer Ingelheim holds a valid patent for Linagliptin in India until August 2023.

Vani Manja, Managing Director, Boehringer Ingelheim India, said “The swift and just actions from the Hon’ble High Court over the past nine months have reaffirmed our faith in Indian legal system in securing the enforcement of patent rights and upholding of patient interests. This also underlines the strength of Boehringer Ingelheim’s patents.

We continue to remain committed to making a positive difference in the lives of patients with our innovator drugs and expect all responsible corporate citizens to uphold Boehringer Ingelheim’s valid patents for innovator drugs.

We believe that upholding patent rights encourage a culture of innovation and R&D in the country.”

In the last nine months, Boehringer Ingelheim has received the following injunctions against generic pharmaceutical companies for patent infringement of its innovator drugs Jardiance (Empagliflozin) and Trajenta (Linagliptin):

Ad-interim injunction granted against Dr. Reddy’s Laboratories for Empagliflozin which was eventually made absolute
Ad-interim injunction granted against MSN Laboratories for Empagliflozin which was eventually made absolute
Ad-interim injunction granted against MacLeods for Linagliptin which eventually was made absolute
Ad-interim injunction granted against Eris Lifesciences Ltd for Linagliptin
Ad-interim injunction granted against MSN Laboratories for Linagliptin
Ad-interim injunction granted against Emcure Pharmaceuticals Ltd for Linagliptin
Ad-interim injunction granted against Optimus Pharma Pvt. Ltd for Linagliptin

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at http://www.boehringer-ingelheim.com

Established in 2003, Boehringer Ingelheim India, manages the India and the neighboring markets operations of the global enterprise. The Company enables access to innovator products as part of its Human Pharma and Animal Health businesses. The focus Human Pharma therapy areas include diabetes, cardiovascular and respiratory conditions. Learn more at http://www.boehringer-ingelheim.in